Protocol B and synthetic biology
WDL technology couples the boundless natural diversity with directed synthetic biology innovation. The company invented a proprietary process, Protocol B™, for the isolation, selection and cultivation of microbiome-derived Clostridia, which has resulted in large, diverse and novel strain libraries. Clostridia is a long known but less understood class of bacteria, with promising implications for nutrition and health thanks to ground-breaking studies and emerging applications in microbiome science. Hundreds to thousands of Clostridia strains can be isolated and cultivated in a matter of days via Protocol B and from diverse physiological and environmental samples. Many strains are previously “unculturable” and most are yet identified, exhibiting characteristics that render them as beneficial platforms for synthetic biology and animal and human gut health.
Additionally, WDL has advanced synthetic biology tools specific for Clostridia, which allows us to further harness the diverse phenotypic traits of these organisms to make bulk and commodity chemicals, specialty chemicals and advanced nutrition products.